These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1606087)

  • 1. Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
    Arienti F; Gambacorti-Passerini C; Borin L; Rivoltini L; Orazi A; Pogliani EM; Corneo G; Parmiani G
    Ann Oncol; 1992 Feb; 3(2):155-62. PubMed ID: 1606087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
    Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF
    Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
    Foa R; Fierro MT; Cesano A; Guarini A; Bonferroni M; Raspadori D; Miniero R; Lauria F; Gavosto F
    Blood; 1991 Aug; 78(4):1041-6. PubMed ID: 1868239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of adhesion molecules on acute leukemic blast cells and sensitivity to normal LAK activity.
    Raspadori D; Lauria F; Ventura MA; Rondelli D; Tura S
    Ann Hematol; 1993 Nov; 67(5):213-6. PubMed ID: 7694662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells.
    Archimbaud E; Thomas X; Campos L; Magaud JP; Fiere D; Doré JF
    Leukemia; 1991 Nov; 5(11):967-71. PubMed ID: 1961038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strength of binding between leukemic blasts and cytotoxic lymphocytes.
    Palucka AK; Waniewski J; Porwit A
    Cytometry; 1996 Apr; 23(4):330-6. PubMed ID: 8900476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Killing activity of lymphokine-activated killer (LAK) cells on fresh acute leukemia cells].
    Zhao TH
    Zhonghua Zhong Liu Za Zhi; 1991 Mar; 13(2):117-9. PubMed ID: 1879289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1.
    Triozzi PL; Eicher DM; Smoot J; Rinehart JJ
    Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjugate formation by leukemic blasts from acute myeloid leukemia with cytotoxic lymphocytes.
    Palucka AK; Porwit A; Reizenstein P
    Leuk Lymphoma; 1993 Nov; 11(5-6):427-33. PubMed ID: 7907248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
    Treichel RS; Olken S
    Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors.
    Oberholtzer E; Contarini M; Veglia F; Cossarizza A; Franceschi C; Geuna M; Provinciali M; Di Stefano G; Sissom J; Brizzi MF; Pegoraro L; Matera L
    Adv Neuroimmunol; 1996; 6(3):233-47. PubMed ID: 8968423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of cytokines and autologous lymphokine-activated killer cells on leukemic bone marrow cells and colonies in AML.
    Braun SW; Gerhartz HH; Schmetzer HM
    Acta Haematol; 2001; 105(4):209-21. PubMed ID: 11528095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.
    Fierro MT; Liao XS; Lusso P; Bonferroni M; Matera L; Cesano A; Lista P; Arione R; Forni G; Foa R
    Leukemia; 1988 Jan; 2(1):50-4. PubMed ID: 3257539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance of leukemic blasts to lymphokine activated killer (LAK)-mediated cytotoxicity is not related to their adhesion properties.
    Palucka AK; Porwit A; Reizenstein P
    Eur J Haematol; 1991 Aug; 47(2):123-7. PubMed ID: 1716215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
    Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
    Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
    Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
    Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer (LAK) cells and cytokines synergize to kill clonal cells in acute myeloid leukemia (AML) in vitro.
    Braun S; Gerhartz HH; Schmetzer HM
    Haematologia (Budap); 2000; 30(4):271-88. PubMed ID: 11204027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
    Mizutani Y; Bonavida B; Nio Y; Yoshida O
    Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.